Johnson & Johnson (J&J) has reported updated results from its Phase 1b/2 OrigAMI-1 trial evaluating amivantamab-vmjw in combination with chemotherapy for patients with RAS/BRAF wild-type metastatic colorectal cancer. The bispecific antibody, which targets epidermal growth factor receptor (EGFR) and MET, achieved confirmed response rates of 73 percent in the first-line setting and 44 percent in the second-line setting. Responses were notably durable, particularly among patients with liver metastases. These findings were presented at the 2026 ASCO GI Symposium and build momentum for the ongoing OrigAMI-2 and OrigAMI-3 pivotal trials.

Why MET resistance in colorectal cancer is becoming an actionable vulnerability

EGFR-targeted therapies remain standard in the RAS/BRAF wild-type colorectal cancer segment, but resistance often emerges early, with MET pathway activation increasingly implicated in post-EGFR progression. By simultaneously targeting EGFR and MET, amivantamab offers a potential workaround to this resistance mechanism, providing rationale for its use in both EGFR-naive and EGFR-exposed populations.

The updated OrigAMI-1 data adds weight to this hypothesis. In the second-line subgroup, the combination of amivantamab and chemotherapy delivered an overall response rate of 44 percent and a median progression-free survival of 9.2 months. These results substantially exceed historical second-line benchmarks, which typically hover around 32 to 36 percent response rates and 5.4 to 6.4 months of median progression-free survival. The data suggest that MET is not just a resistance mechanism but a viable therapeutic target in its own right.

Importantly, the study excluded prior EGFR therapy, allowing investigators to observe MET-driven biology without confounding exposure to anti-EGFR antibodies. This makes the efficacy signal more interpretable, especially as MET overexpression or amplification may serve as a future biomarker to guide treatment selection.

What first-line conversion cases imply for resection strategies in metastatic colorectal cancer

In the first-line cohort, the data was even more compelling. Among patients receiving amivantamab with chemotherapy up front, 73 percent experienced a confirmed response. Notably, four patients were able to undergo curative-intent surgery, a remarkable outcome in a setting where conversion to resection remains rare.

For colorectal cancer patients with liver metastases, durable tumor shrinkage that leads to operability can shift the clinical objective from palliative to potentially curative. The study’s liver metastasis subgroup saw a 57 percent response rate and a median progression-free survival of 11.3 months. These metrics not only challenge the conventional therapeutic ceiling but suggest that biological targeting may create new pathways to surgical eligibility.

Clinicians tracking this evolution are likely to re-examine how conversion therapy is defined in metastatic colorectal cancer. If amivantamab-based regimens continue to yield such outcomes, multidisciplinary treatment planning could begin to incorporate bispecifics more routinely in first-line settings.

Why Johnson & Johnson’s pipeline bets now extend well beyond non-small cell lung cancer

Until recently, amivantamab was considered primarily a non-small cell lung cancer asset, with multiple global approvals in various EGFR mutation subtypes. However, the colorectal data changes that positioning. Johnson & Johnson is now clearly signaling a strategy to expand amivantamab across solid tumor indications that share EGFR or MET dependency.

The company’s decision to launch subcutaneous formulations in its OrigAMI-2 and OrigAMI-3 trials speaks to delivery model ambitions. A transition to subcutaneous dosing could reduce infusion burden, enhance patient compliance, and potentially improve long-term tolerability. These factors could also improve payer receptivity, especially in competitive markets where biosimilar EGFR antibodies are entrenched.

Industry observers point to Johnson & Johnson’s existing immuno-oncology and solid tumor platforms as natural scaffolds for expanding the utility of bispecific antibodies. With the pipeline already supporting combinations with chemotherapy, immunotherapies, and targeted agents, colorectal cancer may be just the starting point for broader deployment.

What obstacles could limit real-world translation of the OrigAMI-1 results

Despite the durability signals and strong first-line response rates, several caveats limit the immediate clinical applicability of OrigAMI-1. First, the study population was carefully selected, with all patients wild-type for KRAS, NRAS, and BRAF, and without HER2 amplification. These biomarkers account for a significant portion of the general colorectal cancer population, meaning real-world eligibility may be narrower than the overall metastatic patient pool.

Second, the exclusion of patients with prior EGFR inhibitor treatment limits insights into whether amivantamab can effectively reverse or overcome acquired EGFR resistance. That question remains highly relevant for oncologists managing patients who progress on first-line EGFR-based regimens and could impact second-line sequencing decisions.

Third, the safety profile, while consistent with known amivantamab and chemotherapy toxicities, still involved neutropenia as the most common Grade 3 or higher adverse event. Four patients discontinued therapy due to treatment-related adverse events, suggesting that while manageable, the dual targeting approach is not without its tolerability trade-offs.

Reimbursement dynamics also remain a potential barrier. Off-patent EGFR monoclonal antibodies are widely accessible and cost-effective. Unless Johnson & Johnson can deliver a compelling pharmacoeconomic case for amivantamab’s use, particularly in second-line settings, market access may hinge on local cost-benefit analyses.

Why bispecific antibodies may be rewriting the playbook in solid tumors

Amivantamab’s trajectory reflects a larger shift in oncology toward modular, pathway-agnostic biologics. Bispecific antibodies, once viewed as complex or niche, are now demonstrating practical versatility across tumor types. By integrating dual pathway targeting, immune activation, and flexible delivery formats, these molecules are challenging assumptions around the limits of monoclonal therapy.

For pharmaceutical developers, this raises strategic questions. Should bispecifics be reserved for biomarker-defined resistance? Or can they displace traditional monoclonals in first-line use where pathway dependencies overlap? The answer may vary by indication, but in colorectal cancer, the durability data from OrigAMI-1 suggests that dual-targeting regimens may not only compete—they may redefine treatment goals entirely.

The upcoming OrigAMI-2 and OrigAMI-3 trials will be critical in answering these questions. With global, randomized designs and a focus on subcutaneous administration, they represent a potential inflection point not just for amivantamab but for the broader role of bispecifics in solid tumor oncology.

Why the regulatory timing and payer landscape will determine how fast amivantamab reaches colorectal cancer patients

The longer-term impact of amivantamab in colorectal cancer will ultimately depend not just on clinical data, but on regulatory strategy and market positioning. Johnson & Johnson has not yet announced any formal plans to file for colorectal cancer indications based on OrigAMI-1, but accelerated pathways could be considered if OrigAMI-2 or OrigAMI-3 replicate or exceed the early efficacy signals. That said, the regulatory bar may be higher for a drug already approved in another tumor type, especially when the current standard of care includes widely available and lower-cost EGFR monoclonal antibodies.

Health technology assessment agencies in Europe, along with U.S. payers, will likely require clear evidence of superiority—not just non-inferiority—over existing doublet regimens before endorsing broader adoption. Additionally, while the subcutaneous formulation under development may offer an edge in real-world use, it must demonstrate equivalent or superior outcomes in randomized settings to offset the cost and complexity of switching patients to a novel delivery platform. In this context, the next two years will be pivotal in determining whether amivantamab becomes a category-defining bispecific in colorectal cancer or remains a niche option for molecularly selected patients.

  amivantamab, dual-targeting bispecifics, EGFR, FOLFIRI, FOLFOX, Johnson & Johnson, MET, metastatic colorectal cancer, oncology, OrigAMI-1, OrigAMI-2, Rybrevant, targeted therapy